Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
US10808031B2 · kind B2 · utility
1Cited by
19References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 21, 2016 |
| Grant date | Oct 20, 2020 |
| Priority date | — |
| Expiry date | Apr 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.